

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/11, A61K 31/70, C07H 21/04	A1	(11) International Publication Number: WO 97/11171 (43) International Publication Date: 27 March 1997 (27.03.97)
(21) International Application Number: PCT/US96/15084 (22) International Filing Date: 19 September 1996 (19.09.96) (30) Priority Data: 08/532,979 22 September 1995 (22.09.95) US (71) Applicant: HYBRIDON, INC. [US/US]; One Innovation Drive, Worcester, MA 01605 (US). (72) Inventor: AGRAWAL, Sudhir, 61 Lamplighter Drive, Shrewsbury, MA 01545 (US). (74) Agents: KERNER, Ann-Louise et al.; Hale & Dorr, 60 State Street, Boston, MA 02109 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF THEIR USE (57) Abstract Disclosed are synthetic, modified oligonucleotides complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit R1 α . The modified oligonucleotides have from about 15 to about 30 nucleotides and are hybrid, inverted hybrid, or inverted chimeric oligonucleotides. Also disclosed are therapeutic compositions containing such oligonucleotides and methods of using the same.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**MODIFIED PROTEIN KINASE A-SPECIFIC
OLIGONUCLEOTIDES AND METHODS OF THEIR USE**

5 FIELD OF THE INVENTION

 The present invention relates to cancer
therapy. More specifically, the present invention
relates to the inhibition of the proliferation of
10 cancer cells using modified antisense
oligonucleotides complementary to nucleic acid
encoding the protein kinase A RI_α subunit.

15 BACKGROUND OF THE INVENTION

 The development of effective cancer therapies
has been a major focus of biomedical research.
Surgical procedures have been developed and used
to treat patients whose tumors are confined to
20 particular anatomical sites. However, at
presentation, only about 25% of patients have
tumors that are truly confined and amenable to
surgical treatment alone (Slapak et al. in
Harrison's Principles of Internal Medicine
25 (Isselbacher et al., eds.) McGraw-Hill, Inc., NY
(1994) pp. 1826-1850). Radiation therapy, like
surgery, is a local modality whose usefulness in
the treatment of cancer depends to a large extent
on the inherent radiosensitivity of the tumor and
30 its adjacent normal tissues. However, radiation
therapy is associated with both acute toxicity and
long term sequelae. Furthermore, radiation
therapy is known to be mutagenic, carcinogenic,
and teratogenic (Slapak et al., *ibid.*).

35

Systemic chemotherapy alone or in combination with surgery and/or radiation therapy is currently the primary treatment available for disseminated malignancies. However, conventional
5 chemotherapeutic agents which either block enzymatic pathways or randomly interact with DNA irrespective of the cell phenotype, lack specificity for killing neoplastic cells. Thus, systemic toxicity often results from standard
10 cytotoxic chemotherapy. More recently, the development of agents that block replication, transcription, or translation in transformed cells, and at the same time defeat the ability of cells to become resistant, has been the goal of
15 many approaches to chemotherapy.

One strategy is to down-regulate the expression of a gene associated with the neoplastic phenotype in a cell. A technique for
20 turning off a single activated gene is the use of antisense oligodeoxynucleotides and their analogues for inhibition of gene expression (Zamecnik et al. (1978) *Proc. Natl. Acad. Sci. (USA)* 75:280-284). An antisense oligonucleotide
25 targeted at a gene involved in the neoplastic cell growth should specifically interfere only with the expression of that gene, resulting in arrest of cancer cell growth. The ability to specifically block or down-regulate expression of such genes
30 provides a powerful tool to explore the molecular basis of normal growth regulation, as well as the opportunity for therapeutic intervention (see, e.g., Cho-Chung (1993) *Curr. Opin. Thera. Patents* 3:1737-1750). The identification of genes that confer a

growth advantage to neoplastic cells as well as other genes causally related to cancer and the understanding of the genetic mechanism(s) responsible for their activation makes the antisense approach to cancer treatment possible.

One such gene encodes the RI_{α} subunit of cyclic AMP (cAMP)-dependent protein kinase A (PKA) (Krebs (1972) *Curr. Topics Cell. Regul.* 5:99-133).

Protein kinase is bound by cAMP, which is thought to have a role in the control of cell proliferation and differentiation (see, e.g., Cho-Chung (1980) *J. Cyclic Nucleotide Res.* 6:163-167).

There are two types of PKA, type I (PKA-I) and type II (PKA-II), both of which share a common C subunit but each containing distinct R subunits, RI and RII, respectively (Beebe et al. in *The Enzymes: Control by Phosphorylation*, 17(A):43-111 (Academic, New York, 1986). The R subunit isoforms differ in tissue distribution (Øyen et al. (1988) *FEBS Lett.* 229:391-394; Clegg et al. (1988) *Proc. Natl. Acad. Sci. (USA)* 85:3703-3707) and in biochemical properties (Beebe et al. in *The Enzymes: Control by Phosphorylation*, 17(A):43-111 (Academic Press, NY, 1986); Cadd et al. (1990) *J. Biol. Chem.* 265:19502-19506). The two general isoforms of the R subunit also differ in their subcellular localization: RI is found throughout the cytoplasm; whereas RI localizes to nuclei, nucleoli, Golgi apparatus and the microtubule-organizing center (see, e.g., Lohmann in *Advances in Cyclic Nucleotide and Protein Phosphorylation Research*, 18:63-117

(Raven, New York, 1984; and Nigg et al. (1985) *Cell* 41:1039-1051).

5 An increase in the level of RI_α expression
has been demonstrated in human cancer cell lines
and in primary tumors, as compared with normal
counterparts, in cells after transformation with
the Ki-ras oncogene or transforming growth factor-
α, and upon stimulation of cell growth with
10 granulocyte-macrophage colony-stimulating factor
(GM-CSF) or phorbol esters (Lohmann in *Advances in
Cyclic Nucleotide and Protein Phosphorylation Research*, 18:63-117
(Raven, New York, 1984); and Cho-Chung (1990)
Cancer Res. 50:7093-7100). Conversely, a decrease
15 in the expression of RI_α has been correlated with
growth inhibition induced by site-selective cAMP
analogs in a broad spectrum of human cancer cell
lines (Cho-Chung (1990) *Cancer Res.* 50:7093-7100).
It has also been determined that the expression of
20 RI/PKA-I and RII/PKA-II has an inverse
relationship during ontogenic development and cell
differentiation (Lohmann in *Advances in Cyclic Nucleotide
and Protein Phosphorylation Research*, Vol. 18, 63-117
(Raven, New York, 1984); Cho-Chung (1990) *Cancer
25 Res.* 50:7093-7100). The RI_α subunit of PKA has
thus been hypothesized to be an ontogenic growth-
inducing protein whose constitutive expression
disrupts normal ontogenic processes, resulting in
a pathogenic outgrowth, such as malignancy
30 (Nesterova et al. (1995) *Nature Medicine* 1:528-533).

Antisense oligonucleotides directed to the
RI_α gene have been prepared. U.S. Patent No.
5,271,941 describes phosphodiester-linked
antisense oligonucleotides complementary to a
5 region of the first 100 N-terminal amino acids of
RI_α which inhibit the expression of RI_α in
leukemia cells *in vitro*. In addition, antisense
phosphorothioate oligodeoxynucleotides
corresponding to the N-terminal 8-13 codons of the
10 RI_α gene was found to reduce *in vivo* tumor growth in
nude mice (Nesterova et al. (1995) *Nature Med.*
1:528-533).

Unfortunately, problems have been encountered
15 with the use of phosphodiester-linked (PO)
oligonucleotides and some phosphorothioate-linked
(PS) oligonucleotides. It is known that nucleases
in the serum readily degrade PO oligonucleotides.
Replacement of the phosphodiester internucleotide
20 linkages with phosphorothioate internucleotide
linkages has been shown to stabilize
oligonucleotides in cells, cell extracts, serum,
and other nuclease-containing solutions (see,
e.g., Bacon et al. (1990) *Biochem. Biophys. Meth.*
25 20:259) as well as *in vivo* (Iversen (1993) *Antisense*
Research and Application (Crooke, ed) CRC Press, 461).
However, some PS oligonucleotides have been found
to exhibit an immunostimulatory response, which in
certain cases may be undesirable. For example,
30 Galbraith et al. (*Antisense Res. & Dev.* (1994) 4:201-
206) disclose complement activation by some PS
oligonucleotides. Henry et al. (*Pharm. Res.* (1994)
11: PPDM8082) disclose that some PS

There is, therefore, a need for modified
5 oligonucleotides directed to cancer-related genes
that retain gene expression inhibition properties
while producing fewer side effects than
conventional oligonucleotides.

10

15

25

It is known that exclusively phosphodiester-
or exclusively phosphorothioate-linked
oligonucleotides directed to the first 100
5 nucleotides of the RI_{α} nucleic acid inhibit cell
proliferation. It is also known that some PS
oligonucleotides cause an immunostimulatory
response in subjects to whom they have been
administered, which may be undesirable in some
10 cases. It has now been discovered that modified
oligonucleotides complementary to the protein
kinase A RI_{α} subunit gene inhibit the growth of
tumors *in vivo*, and that these modified
oligonucleotides have at least the anti-PKA
15 activity of a comparable PO- or PS-linked
oligonucleotide but with fewer side effects.

These findings have been exploited to produce
the present invention, which in a first aspect,
20 includes synthetic hybrid, inverted hybrid, and
inverted chimeric oligonucleotides and
compositions of matter for specifically down-
regulating protein kinase A subunit RI_{α} gene
expression with reduced side effects. Such
25 inhibition of gene expression is useful as an
alternative to mutant analysis for determining the
biological function and role of protein kinase
A-related genes in cell proliferation and tumor
growth. Such inhibition of RI_{α} gene expression
30 can also be used to therapeutically treat diseases
and disorders that are caused by the over-
expression or inappropriate expression of the
gene.

As used herein, the term "synthetic oligonucleotide" includes chemically synthesized polymers of three up to 50, preferably from about 15 to about 30, and most preferably, 18
5 ribonucleotide and/or deoxyribonucleotide monomers connected together or linked by at least one, and preferably more than one, 5' to 3' internucleotide linkage.

10 For purposes of the invention, the term "oligonucleotide sequence that is complementary to a genomic region or an RNA molecule transcribed therefrom" is intended to mean an oligonucleotide that binds to the nucleic acid sequence under
15 physiological conditions, e.g., by Watson-Crick base pairing (interaction between oligonucleotide and single-stranded nucleic acid) or by Hoogsteen base pairing (interaction between oligonucleotide and double-stranded nucleic acid) or by any other
20 means including in the case of a oligonucleotide binding to RNA, causing pseudoknot formation. Binding by Watson-Crick or Hoogsteen base pairing under physiological conditions is measured as a practical matter by observing interference with
25 the function of the nucleic acid sequence.

In one preferred embodiment according to this aspect of the invention, the oligonucleotide is a core region hybrid oligonucleotide comprising a
30 region of at least two deoxyribonucleotides, flanked by 5' and 3' ribonucleotide regions, each having at least four ribonucleotides. A hybrid oligonucleotide having the sequence set forth in

the Sequence Listing as SEQ ID NO:4 is one particular embodiment. In some embodiments, each of the 3' and 5' flanking ribonucleotide regions of an oligonucleotide of the invention
5 comprises at least four contiguous, 2'-O-substituted ribonucleotides.

For purposes of the invention, the term "2'-O-substituted" means substitution of the 2'
10 position of the pentose moiety with an -O- lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or
15 may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or with a hydroxy, an amino or a halo group, but not with a 2'-H group.

20

In some embodiments, each of the 3' and 5' flanking ribonucleotide regions of an oligonucleotide of the invention comprises at least one 2'-O-alkyl substituted ribonucleotide.
25 In one preferred embodiment, the 2'-O-alkyl-substituted nucleotide is a 2'-O-methyl ribonucleotide. In other preferred embodiments, the 3' and 5' flanking ribonucleotide regions of an oligonucleotide of the invention comprises at
30 least four 2'-O-methyl ribonucleotides. In preferred embodiments, the ribonucleotides and deoxyribonucleotides of the hybrid oligonucleotide are linked by phosphorothioate internucleotide linkages. In particular embodiments, this

phosphorothioate region or regions have from about four to about 18 nucleosides joined to each other by 5' to 3' phosphorothioate linkages, and preferably from about 5 to about 18 such phosphorothioate-linked nucleosides. The phosphorothioate linkages may be mixed R_p and S_p enantiomers, or they may be stereoregular or substantially stereoregular in either R_p or S_p form (see Iyer et al. (1995) *Tetrahedron Asymmetry* 6:1051-1054).

In another preferred embodiment according to this aspect of the invention, the oligonucleotide is an inverted hybrid oligonucleotide comprising a region of at least four ribonucleotides flanked by 3' and 5' deoxyribonucleotide regions of at least two deoxyribonucleotides. The structure of this oligonucleotide is "inverted" relative to traditional hybrid oligonucleotides. In some embodiments, the 2'-O-substituted RNA region has from about four to about ten 2'-O-substituted nucleosides joined to each other by 5' to 3' internucleoside linkages, and most preferably from about four to about six such 2'-O-substituted nucleosides. In some embodiments, the oligonucleotides of the invention have a ribonucleotide region comprises at least five contiguous ribonucleotides. In one particularly preferred embodiment, the overall size of the inverted hybrid oligonucleotide is 18. In preferred embodiments, the 2'-O-substituted ribonucleosides are linked to each other through a 5' to 3' phosphorothioate, phosphorodithioate, phosphotriester, or phosphodiester linkages. The

phosphorothioate 3' or 5' flanking region (or regions) has from about four to about 18 nucleosides joined to each other by 5' to 3' phosphorothioate linkages, and preferably from about 5 to about 18 such phosphorothioate-linked nucleosides. In preferred embodiments, the phosphorothioate regions will have at least 5 phosphorothioate-linked nucleosides. One specific embodiment is an oligonucleotide having substantially the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:6. In preferred embodiments of this aspect of the invention, the ribonucleotide region comprise 2'-O-substituted ribonucleotides, such as 2'-O-alkyl substituted ribonucleotides. One particularly preferred embodiment is a hybrid oligonucleotide whose ribonucleotide region comprise at least one 2'-O-methyl ribonucleotide.

In some embodiments, all of the nucleotides in the inverted hybrid oligonucleotide are linked by phosphorothioate internucleotide linkages. In particular embodiments, the deoxyribonucleotide flanking region or regions has from about four to about 18 nucleosides joined to each other by 5' to 3' phosphorothioate linkages, and preferably from about 5 to about 18 such phosphorothioate-linked nucleosides. In some embodiments, the deoxyribonucleotide 3' and 5' flanking regions of the hybrid oligonucleotides of the invention have about 5 phosphorothioate-linked nucleosides. The phosphorothioate linkages may be mixed R_p and S_p enantiomers, or they may be stereoregular or substantially stereoregular in either R_p or S_p

form (see Iyer et al. (1995) *Tetrahedron Asymmetry* 6:1051-1054).

5 Another embodiment is a composition of matter for inhibiting the expression of protein kinase A subunit RI_α with reduced side effects, the composition comprising an inverted hybrid oligonucleotide according to the invention.

10 Yet another preferred embodiment according to this aspect of the invention is an inverted chimeric oligonucleotide comprising an oligonucleotide nonionic region of at least four nucleotides flanked by one or more, and preferably
15 two oligonucleotide phosphorothioate regions. Such a chimeric oligonucleotide has a structure that is "inverted" relative to traditional chimeric oligonucleotides. In one particular embodiment, an inverted chimeric oligonucleotide
20 of the invention has substantially the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1. In preferred embodiments, the oligonucleotide nonionic region comprises about four to about 12 nucleotides joined to each other
25 by 5' to 3' nonionic linkages. In some embodiments, the nonionic region contains alkylphosphonate and/or phosphoramidate and/or phosphotriester internucleoside linkages. In one particular embodiment, the oligonucleotide
30 nonionic region comprises six nucleotides. In some preferred embodiments, the oligonucleotide has a nonionic region having from about six to

about eight methylphosphonate-linked nucleosides, flanked on either side by phosphorothioate regions, each having from about six to about ten phosphorothioate-linked nucleosides. In preferred
5 embodiments, the flanking region or regions are phosphorothioate nucleotides. In some embodiments, the flanking region or regions have from about four to about 24 nucleosides joined to each other by 5' to 3' phosphorothioate linkages,
10 and preferably from about six to about 16 such phosphorothioate-linked nucleosides. In preferred embodiments, the phosphorothioate regions have from about five to about 15 phosphorothioate-linked nucleosides. The phosphorothioate linkages
15 may be mixed R_p and S_p enantiomers, or they may be stereoregular or substantially stereoregular in either R_p or S_p form (see Iyer et al. (1995) *Tetrahedron Asymmetry* 6:1051-1054).

20 Another embodiment of this aspect of the invention is a composition of matter for inhibiting the expression of protein kinase A subunit RI_α with reduced side effects, the composition comprising an inverted chimeric
25 oligonucleotide according to the invention.

Another aspect of the invention is a method of inhibiting the proliferation of cancer cells *in vitro*. In this method, an oligonucleotide of the
30 invention is administered to the cells.

Yet another aspect is a therapeutic composition comprising an oligonucleotide of the invention in a pharmaceutically acceptable carrier.

5

A method of treating cancer in an afflicted subject with reduced side effects is another aspect of the invention. This method comprises administering a therapeutic composition of the invention to the subject in which the protein kinase A subunit RI_α gene is being over-expressed.

10

Those skilled in the art will recognize that the elements of these preferred embodiments can be combined and the inventor does contemplate such combination. For example, 2'-O-substituted ribonucleotide regions may well include from one to all nonionic internucleoside linkages. Alternatively, nonionic regions may have from one to all 2'-O-substituted ribonucleotides. Moreover, oligonucleotides according to the invention may contain combinations of one or more 2'-O-substituted ribonucleotide region and one or more nonionic region, either or both being flanked by phosphorothioate regions (See *Nucleosides & Nucleotides* 14:1031-1035 (1995) for relevant synthetic techniques).

15

20

25

BRIEF DESCRIPTION OF THE DRAWINGS

5 The foregoing and other objects of the present invention, the various features thereof, as well as the invention itself may be more fully understood from the following description, when read together with the accompanying drawings in which:

10 FIG. 1 is a graphic representation showing the effect of modified oligonucleotides of the invention on tumor size in a mouse relative to various controls.

DESCRIPTION OF THE PREFERRED EMBODIMENT

5 The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The issued U.S. patents, allowed applications, published foreign applications, and references cited herein are hereby incorporated by reference.

10 Synthetic oligonucleotides of the hybrid, inverted hybrid, and inverted chimeric oligonucleotides as described above.

15 The present invention provides such synthetic hybrid, inverted hybrid, and inverted chimeric oligonucleotides have a nucleotide sequence complementary to a genomic region or an RNA molecule transcribed therefore encoding the RI_α subunit of protein kinase A (PKA). These
20 oligonucleotides are about 15 to about 30 nucleotides in length, preferably about 15 to 25 nucleotides in length, but most preferably, are about 18 nucleotides long. The sequence of this gene is known. Thus, an oligonucleotide of the
25 invention can have any nucleotide sequence complementary to any region of the gene. Three non-limiting examples of an 18mer of the invention has the sequence set forth below in TABLE 1 as SEQ
30 ID NOS:1, 4, and 6.

TABLE 1

5	Oligo #	Sequence (5' → 3')	Type	SEQ ID NO:
	164	GCG TGC CTC CTC ACT GGC	Control	1
	167	GCG <u>CGC</u> CTC CTC <u>GCT</u> GGC	Mismatched Control	2
	188	GCA TGC <u>TTC</u> <u>CAC</u> <u>ACA</u> GGC	Mismatched Control	3
10	165	*** * GCG UGC CTC CTC ACU *** GGC	Hybrid	4
	168	*** * GCG <u>CGC</u> CTC CTC <u>GU</u> *** GGC	Mismatched Hybrid (Control)	5
15	165a	*** * GCA UGC <u>ATC</u> CGC <u>ACA</u> *** GGC	Mismatched Hybrid (Control)	9
	166	*** ** GCG TGC CUC CUC ACT GGC	Inverted Hybrid	6
	169	*** ** GCG <u>CGC</u> CUC CUC <u>GCT</u> GGC	Mismatched Inverted Hybrid (Control)	7
20	189	*** ** GCA TGC <u>AUC</u> <u>CGC</u> <u>ACA</u> GGC	Mismatched Inverted Hybrid (Control)	8
	190	*** ** GCG TGC CTC CTC ACT GGC	Inverted Chimeric	1
25	191	*** ** GCG <u>CGC</u> CTC CTC <u>GCT</u> GGC	Mismatched Inverted Chimeric (Control)	2

X = mismatched base
 * = ribonucleotide
 • = methylphosphonate nucleotide

30

Oligonucleotides having greater than 18
 oligonucleotides are also contemplated by the
 invention. These oligonucleotides have up to 25
 additional nucleotides extending from the 3', or
 5' terminus, or from both the 3' and 5' termini

of, for example, the 18mer with SEQ ID NOS:1, 4, or 6, without diminishing the ability of these oligonucleotides to down-regulate RI_{α} gene expression. Alternatively, other oligonucleotides of the invention may have fewer nucleotides than, for example, oligonucleotides having SEQ ID NOS:1, 4, or 6. Such shortened oligonucleotides maintain at least the antisense activity of the parent oligonucleotide to down-regulate the expression of the RI_{α} gene, or have greater activity.

The oligonucleotides of the invention can be prepared by art recognized methods. Oligonucleotides with phosphorothioate linkages can be prepared manually or by an automated synthesizer and then processed using methods well known in the field such as phosphoramidite (reviewed in Agrawal et al. (1992) *Trends Biotechnol.* 10:152-158, *see, e.g.,* Agrawal et al. (1988) *Proc. Natl. Acad. Sci. (USA)* 85:7079-7083) or H-phosphonate (*see, e.g.,* Froehler (1986) *Tetrahedron Lett.* 27:5575-5578) chemistry. The synthetic methods described in Bergot et al. (*J. Chromatog.* (1992) 559:35-42) can also be used. Examples of other chemical groups include alkylphosphonates, phosphorodithioates, alkylphosphonothioates, phosphoramidates, 2'-O-methyls, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. Oligonucleotides with these linkages can be prepared according to known methods (*see, e.g.,* Goodchild (1990) *Bioconjugate Chem.* 2:165-187; Agrawal et al. (*Proc. Natl. Acad. Sci. (USA)* (1988) 85:7079-7083); Uhlmann et al. (*Chem. Rev.* (1990) 90:534-583;

and Agrawal et al. (*Trends Biotechnol.* (1992) 10:152-158)).

Preferred hybrid, inverted hybrid, and
5 inverted chimeric oligonucleotides of the
invention may have other modifications which do
not substantially affect their ability to
specifically down-regulate RI_{α} gene expression.
These modifications include those which are
10 internal or are at the end(s) of the
oligonucleotide molecule and include additions to
the molecule at the internucleoside phosphate
linkages, such as cholesteryl or diamine compounds
with varying numbers of carbon residues between
15 the two amino groups, and terminal ribose,
deoxyribose and phosphate modifications which
cleave, or crosslink to the opposite chains or to
associated enzymes or other proteins which bind to
the RI_{α} nucleic acid. Examples of such
20 oligonucleotides include those with a modified
base and/or sugar such as arabinose instead of
ribose, or a 3', 5'-substituted oligonucleotide
having a sugar which, at one or both its 3' and 5'
positions is attached to a chemical group other
25 than a hydroxyl or phosphate group (at its 3' or
5' position). Other modified oligonucleotides are
capped with a nuclease resistance-conferring bulky
substituent at their 3' and/or 5' end(s), or have
a substitution in one or both nonbridging oxygens
30 per nucleotide. Such modifications can be at some
or all of the internucleoside linkages, as well as
at either or both ends of the oligonucleotide
and/or in the interior of the molecule (reviewed

in Agrawal et al. (1992) *Trends Biotechnol.* 10:152-158).

5 The invention also provides therapeutic
compositions suitable for treating undesirable,
uncontrolled cell proliferation or cancer comprise
at least one oligonucleotide in accordance with
the invention, capable of specifically down-
regulating expression of the RI_α gene, and a
10 pharmaceutically acceptable carrier or diluent.
It is preferred that an oligonucleotide used in
the therapeutic composition of the invention be
complementary to at least a portion of the RI_α
genomic region, gene, or RNA transcript thereof.

15 As used herein, a "pharmaceutically or
physiologically acceptable carrier" includes any
and all solvents (including but limited to
lactose), dispersion media, coatings,
20 antibacterial and antifungal agents, isotonic and
absorption delaying agents and the like. The use
of such media and agents for pharmaceutically
active substances is well known in the art.
Except insofar as any conventional media or agent
25 is incompatible with the active ingredient, its
use in the therapeutic compositions of the
invention is contemplated. Supplementary active
ingredients can also be incorporated into the
compositions.

30 Several preferred therapeutic composition of
the invention suitable for inhibiting cell
proliferation *in vitro* or *in vivo* or for treating
cancer in humans in accordance with the methods of

the invention comprises about 25 to 75 mg of a lyophilized oligonucleotide(s) having SEQ ID NOS:1, 4, and/or 6, and 20-75 mg lactose, USP, which is reconstituted with sterile normal saline to the therapeutically effective dosages described herein.

The invention also provides methods for treating humans suffering from disorders or diseases wherein the RI_g gene is incorrectly or over-expressed. Such a disorder or disease that could be treated using this method includes tumor-forming cancers such as, but not limited to, human colon carcinoma, breast carcinoma, gastric carcinoma, and neuroblastoma. In the method of the invention, a therapeutically effective amount of a composition of the invention is administered to the human. Such methods of treatment according to the invention, may be administered in conjunction with other therapeutic agents.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical formulation or method that is sufficient to show a meaningful subject or patient benefit, i.e., a reduction in tumor growth or in the expression of proteins which cause or characterize the cancer. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect,

whether administered in combination, serially or simultaneously.

5 A "therapeutically effective manner" refers
to a route, duration, and frequency of
administration of the pharmaceutical formulation
which ultimately results in meaningful patient
benefit, as described above. In some embodiments
of the invention, the pharmaceutical formulation
10 is administered via injection, sublingually,
rectally, intradermally, orally, or enterally in
bolus, continuous, intermittent, or continuous,
followed by intermittent regimens.

15 The therapeutically effective amount of
synthetic oligonucleotide in the pharmaceutical
composition of the present invention will depend
upon the nature and severity of the condition
being treated, and on the nature of prior
20 treatments which the patient has undergone.
Ultimately, the attending physician will decide
the amount of synthetic oligonucleotide with which
to treat each individual patient. Initially, the
attending physician will administer low doses of
25 the synthetic oligonucleotide and observe the
patient's response. Larger doses of synthetic
oligonucleotide may be administered until the
optimal therapeutic effect is obtained for the
patient, and at that point the dosage is not
30 increased further. It is contemplated that the
dosages of the pharmaceutical compositions
administered in the method of the present
invention should contain about 0.1 to 5.0 mg/kg
body weight per day, and preferably 0.1 to 2.0

mg/kg body weight per day. When administered systemically, the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 μM to about 10 μM . Preferably, the concentration of oligonucleotide at the site of aberrant gene expression should be from about 0.01 μM to about 10 μM , and most preferably from about 0.05 μM to about 5 μM . However, for localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated. It may be desirable to administer simultaneously or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention when individual as a single treatment episode.

Administration of pharmaceutical compositions in accordance with invention or to practice the method of the present invention can be carried out in a variety of conventional ways, such as by oral ingestion, enteral, rectal, or transdermal administration, inhalation, sublingual administration, or cutaneous, subcutaneous, intramuscular, intraocular, intraperitoneal, or intravenous injection, or any other route of administration known in the art for administering therapeutic agents.

30

When the composition is to be administered orally, sublingually, or by any non-injectable route, the therapeutic formulation will preferably include a physiologically acceptable carrier, such

as an inert diluent or an assimilable edible carrier with which the composition is administered. Suitable formulations that include pharmaceutically acceptable excipients for
5 introducing compounds to the bloodstream by other than injection routes can be found in *Remington's Pharmaceutical Sciences* (18th ed.) (Genarro, ed. (1990) Mack Publishing Co., Easton, PA). The oligonucleotide and other ingredients may be
10 enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. The therapeutic compositions may be incorporated with excipients and used in the form of ingestible tablets, buccal
15 tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. When the therapeutic composition is administered orally, it may be mixed with other food forms and pharmaceutically acceptable flavor enhancers.
20 When the therapeutic composition is administered enterally, they may be introduced in a solid, semi-solid, suspension, or emulsion form and may be compounded with any number of well-known, pharmaceutically acceptable additives. Sustained
25 release oral delivery systems and/or enteric coatings for orally administered dosage forms are also contemplated such as those described in U.S. Patent Nos. 4,704,295, 4,556,552, 4,309,404, and 4,309,406.

30

When a therapeutically effective amount of composition of the invention is administered by injection, the synthetic oligonucleotide will preferably be in the form of a pyrogen-free,

parenterally-acceptable, aqueous solution. The preparation of such parenterally-acceptable solutions, having due regard to ph, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for injection should contain, in addition to the synthetic oligonucleotide, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile. It must be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms, such as bacterial and fungi. The carrier can be a solvent or dispersion medium. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents. Prolonged absorption of the injectable therapeutic agents can be brought about by the use of the compositions of agents delaying absorption. Sterile injectable solutions are prepared by incorporating the oligonucleotide in

the required amount in the appropriate solvent, followed by filtered sterilization.

5 The pharmaceutical formulation can be administered in bolus, continuous, or intermittent dosages, or in a combination of continuous and intermittent dosages, as determined by the physician and the degree and/or stage of illness of the patient. The duration of therapy using the
10 pharmaceutical composition of the present invention will vary, depending on the unique characteristics of the oligonucleotide and the particular therapeutic effect to be achieved, the limitations inherent in the art of preparing such
15 a therapeutic formulation for the treatment of humans, the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. Ultimately the attending physician will decide on the
20 appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

25 Compositions of the invention are useful for inhibiting or reducing the proliferation of cancer or tumor cells *in vitro*. A synthetic oligonucleotide of the invention is administered to the cells in an amount sufficient to enable the binding of the oligonucleotide to a complementary genomic region
30 or RNA molecule transcribed therefrom encoding the RI_α subunit. In this way, expression of PKA is decreased, thus inhibiting or reducing cell proliferation.

Compositions of the invention are also useful for treating cancer or uncontrolled cell proliferation in humans. In this method, a therapeutic formulation including an antisense oligonucleotide of the invention is provided in a physiologically acceptable carrier. The individual is then treated with the therapeutic formulation in an amount sufficient to enable the binding of the oligonucleotide to the PKA RI_α genomic region or RNA molecule transcribed therefrom in the infected cells. In this way, the binding of the oligonucleotide inhibits or down-regulates RI_α expression and hence the activity of PKA.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of at least one or more therapeutic compositions of the invention is administered to a subject afflicted with a cancer. An anticancer response showing a decrease in tumor growth or size or a decrease in RI_α expression is considered to be a positive indication of the ability of the method and pharmaceutical formulation to inhibit or reduce cell growth and thus, to treat cancer in humans.

At least one therapeutic composition of the invention may be administered in accordance with the method of the invention either alone or in combination with other known therapies for cancer. When co-administered with one or more other therapies, the compositions of the invention may be administered either simultaneously with the

other treatment(s), or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering the compositions of the invention in combination with the other therapy.

The following examples illustrate the preferred modes of making and practicing the present invention, but are not meant to limit the scope of the invention since alternative methods may be utilized to obtain similar results.

EXAMPLE 1

Synthesis, Deprotection, and Purification of Oligonucleotides

Oligonucleotide phosphorothioates were synthesized using an automated DNA synthesizer (Model 8700, Biosearch, Bedford, MA) using a beta-cyanoethyl phosphoramidate approach on a 10 micromole scale. To generate the phosphorothioate linkages, the intermediate phosphite linkage obtained after each coupling was oxidized using 3H, 1,2-benzodithiole-3H-one-1,1-dioxide (see Beaucage, in *Protocols for Oligonucleotides and Analogs: Synthesis and Properties*, Agrawal (ed.), (1993) Humana Press, Totowa, NJ, pp. 33-62). Similar synthesis was carried out to generate phosphodiester linkages, except that a standard oxidation was carried out using standard iodine reagent. Synthesis of inverted chimeric oligonucleotide was carried out in the same manner, except that methylphosphonate linkages were assembled using nucleoside methylphosphonamidite (Glen Research,

Sterling, VA), followed by oxidation with 0.1 M iodine in tetrahydrofuran/2,6-lutidine/water (75:25:0.25) (see Agrawal & Goodchild (1987) *Tet. Lett.* 28:3539-3542). Hybrids and inverted hybrid
5 oligonucleotides were synthesized similarly, except that the segment containing 2'-O-methylribonucleotides was assembled using 2'-O-methylribonucleoside phosphoramidite, followed by
10 oxidation to a phosphorothioate or phosphodiester linkage as described above. Deprotection and purification of oligonucleotides was carried out according to standard procedures, (see Padmapriya et al. (1994) *Antisense Res. & Dev.* 4:185-199), except
15 for oligonucleotides containing methylphosphonate-containing regions. For those oligonucleotides, the CPG-bound oligonucleotide was treated with concentrated ammonium hydroxide for 1 hour at room temperature, and the supernatant was removed and
20 evaporated to obtain a pale yellow residue, which was then treated with a mixture of ethylenediamine/ethanol (1:1 v/v) for 6 hours at room temperature and dried again under reduced pressure.

25

EXAMPLE 2*In Vitro* Complement Activation Studies

30

To determine the relative effect of inverted hybrid or inverted chimeric structure on oligonucleotide-mediated depletion of complement, the following experiments were performed. Venous blood was collected from healthy adult human volunteers. Serum was prepared for hemolytic

complement assay by collecting blood into vacutainers (Becton Dickinson #6430 Franklin Lakes, NJ) without commercial additives. Blood was allowed to clot at room temperature for 30 minutes, chilled on ice for 15 minutes, then centrifuged at 4°C to separate serum. Harvested serum was kept on ice for same day assay or, alternatively, stored at -70°C. Buffer, or an oligonucleotide sample was then incubated with the serum. The oligonucleotides tested were 25mer oligonucleotide phosphodiesteres or phosphorothioates, 25mer hybrid oligonucleotides, 25mer inverted hybrid oligonucleotides, 25mer chimeric oligonucleotides, and 25mer inverted chimeric oligonucleotides. Representative hybrid oligonucleotides were composed of seven to 13 2-O-methyl ribonucleotides flanked by two regions of six to nine deoxyribonucleotides each. Representative 25mer inverted hybrid oligonucleotides were composed of 17 deoxyribonucleotides flanked by two regions of four ribonucleotides each. Representative 25mer chimeric oligonucleotides were composed of six methylphosphonate deoxyribonucleotides and 19 phosphorothioate deoxyribonucleotides. Representative inverted chimeric oligonucleotides were composed of from 16 to 17 phosphorothioate deoxyribonucleotides flanked by regions of from two to seven methylphosphonate deoxyribonucleotides, or from six to eight methylphosphonate deoxyribonucleotides flanked by nine to ten phosphorothioate deoxyribonucleotides, or two phosphorothioate regions ranging from two to 12 oligonucleotides, flanked by three

phosphorothioate regions ranging in size from two to six nucleotides in length. A standard CH50 assay (See Kabat and Mayer (eds), *Experimental Immunochimistry*, 2d Ed., Springfield, IL, CC Thomas, p. 125) for complement-mediated lysis of sheep red blood cells (Colorado Serum Co.) sensitized with anti-sheep red blood cell antibody (hemolysin, Diamedix, Miami, FL) was performed, using duplicate determinations of at least five dilutions of each test serum, then hemoglobin release into cell-free supernates was measured spectrophotometrically at 541 nm.

EXAMPLE 3

In Vitro Mitogenicity Studies Using Mouse Spleen

To determine the relative effect of inverted hybrid or inverted chimeric structure on oligonucleotide-mediated mitogenicity, the following experiments were performed. Spleen was taken from a male CD1 mouse (4-5 weeks, 20-22 g; Charles River, Wilmington, MA). Single cell suspensions were prepared by gently mincing with frosted edges of glass slides. Cells were then cultured in RPMI complete media (RPMI media supplemented with 10% fetal bovine serum (FBS), 50 micromolar 2-mercaptoethanol (2-ME), 100 U/ml penicillin, 100 micrograms/ml streptomycin, 2 mM L-glutamine). To minimize oligonucleotide degradation, FBS was first heated for 30 minutes at 65°C (phosphodiester-containing oligonucleotides) or 56°C (all other oligonucleotides). Cells were plated in 96 well dishes at 100,000 cells per well (volume of 100

microliters/well). One type of each oligonucleotide described in Example 2 above in 10 microliters TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) was added to each well. After 44 hours
5 of culturing at 37°C, one microcurie tritiated thymidine (Amersham, Arlington Heights, IL) was added in 20 microliters RPMI media for a 4 hour pulse labelling. The cells were then harvested in an automatic cell harvester (Skatron, Sterling,
10 VA) and the filters were assessed using a scintillation counter. In control experiments for mitogenicity, cells were treated identically, except that either media (negative control) or concanavalin A (positive control) was added to the
15 cells in place of the oligonucleotides.

All of the inverted hybrid oligonucleotides proved to be less immunogenic than phosphorothioate oligonucleotides. Inverted
20 hybrid oligonucleotides having phosphodiester linkages in the 2'-O-methyl region appeared to be slightly less immunogenic than those containing phosphorothioate linkages in that region. No significant difference in mitogenicity was
25 observed when the 2'-O-methyl ribonucleotide region was pared down from 13 to 11 or to 9 nucleotides. Inverted chimeric oligonucleotides were also generally less mitogenic than phosphorothioate oligonucleotides. In addition,
30 these oligonucleotides appeared to be less mitogenic than traditional chimeric oligonucleotides, at least in cases in which the traditional chimeric oligonucleotides had significant numbers of methylphosphonate linkages

near the 3' end. Increasing the number of methylphosphonate linkers in the middle of the oligonucleotide from 5 to 6 or 7 did not appear to have a significant effect on mitogenicity. These results indicate that incorporation of inverted hybrid or inverted chimeric structure into an oligonucleotide can reduce its mitogenicity.

EXAMPLE 4

10 In Vitro Mitogenicity Studies Using Human Blood

To determine the relative effect of inverted hybrid or inverted chimeric structure on oligonucleotide-induced mitogenicity, the following experiments were performed. Venous blood was collected from healthy adult human volunteers. Plasma for clotting time assay was prepared by collecting blood into siliconized vacutainers with sodium citrate (Becton Dickinson #367705), followed by two centrifugations at 4°C to prepare platelet-poor plasma. Plasma aliquots were kept on ice, spiked with various test oligonucleotides described in Example 2 above, and either tested immediately or quickly frozen on dry ice for subsequent storage at -20°C prior to coagulation assay. Activated partial thromboplastin time (aPTT) was performed in duplicate on an Electra 1000C (Medical Laboratory Automation, Mount Vernon, NY) according to the manufacturer's recommended procedures, using Actin FSL (Baxter Dade, Miami, FL) and calcium to initiate clot formation, which was measured photometrically. Prolongation of aPTT was taken

as an indication of clotting inhibition side effect produced by the oligonucleotide.

Traditional phosphorothioate oligonucleotides
5 produced the greatest prolongation of aPTT, of all
of the oligonucleotides tested. Traditional
hybrid oligonucleotides produced somewhat reduced
prolongation of aPTT. In comparison with
traditional phosphorothioate or traditional hybrid
10 oligonucleotides, all of the inverted hybrid
oligonucleotides tested produced significantly
reduced prolongation of aPTT. Inverted hybrid
oligonucleotides having phosphodiester linkages in
the 2'-O-substituted ribonucleotide region had the
15 greatest reduction in this side effect, with one
such oligonucleotide having a 2'-O-methyl RNA
phosphodiester region of 13 nucleotides showing
very little prolongation of aPTT, even at
oligonucleotide concentrations as high as 100
20 micrograms/ml. Traditional chimeric
oligonucleotides produce much less prolongation of
aPTT than do traditional phosphorothioate
oligonucleotides. Generally, inverted chimeric
oligonucleotides retain this characteristic. At
25 least one inverted chimeric oligonucleotide,
having a methylphosphonate region of seven
nucleotides flanked by phosphorothioate regions of
nine nucleotides, gave better results in this
assay than the traditional chimeric
30 oligonucleotides at all but the highest
oligonucleotide concentrations tested. These
results indicate that inverted hybrid and inverted
chimeric oligonucleotides may provide advantages
in reducing the side effect of clotting inhibition

when they are administered to modulate gene expression *in vivo*.

EXAMPLE 5

In Vivo Complement Activation Studies

5

Rhesus monkeys (4-9 kg body weight) are acclimatized to laboratory conditions for at least 7 days prior to the study. On the day of the study, each animal is lightly sedated with ketamine-HCl (10 mg/kg) and diazepam (0.5 mg/kg). Surgical level anesthesia is induced and maintained by continuous ketamine intravenous drip throughout the procedure. The oligonucleotides described in Example 2 above are dissolved in normal saline and infused intravenously via a cephalic vein catheter, using a programmable infusion pump at a delivery rate of 0.42 mg/minute. For each oligonucleotide, doses of 0, 0.5, 1, 2, 5 and 10 mg/kg are administered to two animals each over a 10 minute infusion period. Arterial blood samples are collected 10 minutes prior to oligonucleotide administration and 2, 5, 10, 20, 40 and 60 minutes after the start of the infusion, as well as 24 hours later. Serum is used for determining complement CH50, using the conventional complement-dependent lysis of sheep erythrocyte procedure (see Kabat and Mayer, 1961, *supra*). At the highest dose, phosphorothioate oligonucleotide causes a decrease in serum complement CH50 beginning within 5 minutes of the start of infusion. Inverted hybrid and chimeric oligonucleotides are expected to show a much reduced or undetectable decrease in serum complement CH50 under these conditions.

10
15
20
25
30

EXAMPLE 6**In Vivo Mitogenicity Studies**

CD1 mice are injected intraperitoneally with
5 a dose of 50 mg/kg body weight of oligonucleotide
described in Example 2 above. Forty-eight hours
later, the animals are euthanized and the spleens
are removed and weighed. Animals treated with
inverted hybrid or inverted hybrid
10 oligonucleotides are expected to show no
significant increase in spleen weight, while those
treated with oligonucleotide phosphorothioates are
expected to show modest increases in spleen
weight.

15

EXAMPLE 7**In Vivo Clotting Studies**

Rhesus monkeys are treated as in Example 5.
20 From the whole blood samples taken, plasma for
clotting assay is prepared, and the assay
performed, as described in Example 4. It is
expected that prolongation of aPTT will be
substantially reduced for both inverted hybrid
25 oligonucleotides and for inverted chimeric
oligonucleotide, relative to traditional
oligonucleotide phosphorothioates.

EXAMPLE 8**RNase H Activity Studies**

To determine the ability of inverted hybrid
5 oligonucleotides and inverted chimeric
oligonucleotides to activate RNase H when bound to
a complementary RNA molecule, the following
experiments were performed. Each type of
oligonucleotide described in Example 2 above was
10 incubated together with a molar equivalent
quantity of complimentary oligoribonucleotide
(0.266 micromolar concentration of each), in a
cuvette containing a final volume of 1 ml RNase H
buffer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 0.1 M
15 KCl, 2% glycerol, 0.1 mM DTT). The samples were
heated to 95°C, then cooled gradually to room
temperature to allow annealing to form duplexes.
Annealed duplexes were incubated for 10 minutes at
37°C, then 5 units RNase H was added and data
20 collection commenced over a three hour period.
Data was collected using a spectrophotometer (GBC
920, GBC Scientific Equipment, Victoria,
Australia) at 259 nm. RNase H degradation was
determined by hyperchromic shift.

25

Phosphodiester oligonucleotides were very
good co-substrates for RNase H-mediated
degradation of RNA, with a degradative half-life
of 8.8 seconds. Phosphorothioate oligonucleotides
30 produced an increased half-life of 22.4 seconds.
Introduction of a 2'-O-methyl ribonucleotide
segment at either end of the oligonucleotide
further worsened RNase H activity (half-life =
32.7 seconds). In contrast, introducing a 2'-O-

methy1 segment into the middle of the oligonucleotide (inverted hybrid structure) always resulted in improved RNase H-mediated degradation. When a region of 13 2'-O-methylribonucleoside phosphodiester was flanked on both sides by phosphorothioate DNA, the best RNase H activity was observed, with a half-life of 7.9 seconds. Introduction of large blocks of methylphosphonate-linked nucleosides at the 3' end of the oligonucleotide either had no effect or caused further deterioration of RNase H activity even when in a chimeric configuration. Introduction of methylphosphonate linked nucleosides at the 5' end, however, improved RNase H activity, particularly in a chimeric configuration with a single methylphosphonate linker at the 3' end (best half-life = 8.1 seconds). All inverted chimeric oligonucleotides with methylphosphonate core regions flanked by phosphorothioate regions gave good RNase results, with a half-life range of 9.3 to 14.4 seconds. These results indicate that the introduction of inverted hybrid or inverted chimeric structure into phosphorothioate-containing oligonucleotides can restore some or all of the ability of the oligonucleotide to act as a co-substrate for RNase H, a potentially important attribute for an effective antisense agent.

30

EXAMPLE 9**Melting Temperature Studies**

35

To determine the effect of inverted hybrid or inverted chimeric structure on stability of the duplex formed between an antisense oligonucleotide

and a target molecule, the following experiments were performed. Thermal melting (T_m) data were collected using a spectrophotometer (GBC 920, GBC Scientific Equipment, Victoria, Australia), which
5 has six 10 mm cuvettes mounted in a dual carousel. In the T_m experiments, the temperature was directed and controlled through a peltier effect temperature controller by a computer, using software provided by GBC, according to the
10 manufacturer's directions. T_m data were analyzed by both the first derivative method and the mid-point method, as performed by the software. T_m experiments were performed in a buffer containing 10 mM PIPES, pH 7.0, 1 mM EDTA, 1 M NaCl. A
15 refrigerated bath (VWR 1166, VWR, Boston, MA) was connected to the peltier-effect temperature controller to absorb the heat. Oligonucleotide strand concentration was determined using absorbance values at 260 nm, taking into account
20 extinction coefficients.

EXAMPLE 10

In Vivo Studies with Human Tumor Cells

25 LS-174T human colon carcinoma cells (1×10^6 cells, ATCC No. CL188, American Type Culture Collection, Rockville, Md.) were inoculated subcutaneously (s.c.) into the left flank of athymic SCID female mice. A single dose of RI_4
30 antisense hybrid (Oligo 164, SEQ ID NO:4), inverted hybrid (Oligo 166, SEQ ID NO:6), or inverted chimeric (Oligo 190, SEQ ID NO:1) oligonucleotides or control oligonucleotide (Oligo 169, SEQ ID NO:7); Oligo 168 (SEQ ID NO:5); Oligo

188, SEQ ID NO:3)) as shown in Table 1 (1 mg per 0.1 ml saline per mouse), or saline (0.1 ml per mouse), was injected s.c. into the right flank of mice when tumor size reached 80 to 100 mg at about 1 week after cell inoculation. Tumor volumes were obtained from daily measurement of the longest and shortest diameters and calculation by the formula, $4/3\pi r^3$ where $r = (\text{length} + \text{width})/4$. At each indicated time, two animals from the control and antisense-treated groups were killed, and tumors were removed and weighed.

The results are shown in FIG. 1. The size of the tumor in the animal treated with the inverted hybrid oligonucleotide 166 having SEQ ID NO:6 was surprisingly smaller from three days after injection onward than the phosphorothioate oligonucleotide 164 having SEQ ID NO:1. That this effect was sequence-specific is also demonstrated in FIG. 1: control oligonucleotide 168 (SEQ ID NO:3) has little ability to keep tumor size at a minimum relative to the hybrid and inverted hybrid oligonucleotides.

In another study, SCID mice with established LS-174T human tumors 50 to 150 mg in size were orally administered hybrid oligonucleotides dissolved in physiological saline (0.9% NaCl) at a concentration of 25 mg/ml. These oligonucleotides had SEQ ID NO:4 or NO:9 and had four 2'-O methyl-substituted ribonucleotides at both their 3' and 5' termini. The oligonucleotide having SEQ ID NO:4 is complementary to a portion of mRNA encoding protein kinase A. The oligonucleotide

having SEQ ID NO:9 is a mismatched control.
Saline or one or the other of these
oligonucleotides was administered to each of the
fasted animals via_gavage at 1 mg/kg, 10 mg/kg,
5 50 mg/kg, or 100 mg/kg body weight of the animal.
Other animals were administered 10 mg/kg anti-PKA
oligonucleotide having SEQ ID NO:4 via
intraperitoneal injection. Doses were based on
the pretreatment body weight and rounded to the
10 nearest 0.01 ml. After dosing, each animal was
placed in a metabolism cage and fed with
commercial diet and water *ad libitum*.

Tumor growth was monitored by measuring tumor
15 size with calipers. Two perpendicular diameters
of the tumor were measured before treatment, and
then once a day for seven days after treatment.
Tumor weight was calculated as follows:

20
$$\text{Tumor weight (mg)} = 1/2 \times A \times B^2 \times 1000$$

where A is the long diameter (cm), and B is the
short diameter (cm).

25

The results, calculated as percent of saline control-treated tumor, are shown below in TABLE 2.

TABLE 2

5

10

15

SEQ ID NO.:	Group	Day 3	Day 6	Day 7
	Control (Saline)	100	100	100
9	HYB0295-Oral 50 mg/kg	83.1	99.9	84.6
4	HYB0165-Oral 1 mg/kg	73.6	79.8	76.7
	10 mg/kg	60.3	64.3	60.7
	50 mg/kg	54	78.6	75.8
	100 mg/kg	60.2	67.7	65.4
4	HYB0165-I.P. 10 mg/kg	65.6	69.3	71.4

20

25

Not only was tumor growth inhibited at each dose of protein kinase A-specific oligonucleotide administered starting at one day after treatment, but tumor size was also diminished. These results demonstrate the ability of the method of the invention to inhibit human tumor growth in mammals.

EXAMPLE 11**Photoaffinity Labelling and
Immunoprecipitation of RI_α Subunits**

5

The tumors are homogenized with a Teflon/glass homogenizer in ice-cold buffer 10 (Tris-HCl, pH 7.4, 20 mM; NaCl, 100 mM; NP-40, 1%; sodium deoxycholate, 0.5%; MgCl₂, 5 mM; pepstatin, 10 0.1 mM; antipain, 0.1 mM; chymostatin, 0.1 mM; leupeptin, 0.2 mM; aprotinin, 0.4 mg/ml; and soybean trypsin inhibitor, 0.5 mg/ml; filtered through a 0.45-μm pore size membrane), and centrifuged for 5 min in an Eppendorf microfuge at 15 4°C. The supernatants are used as tumor extracts.

The amount of PKA RI_α subunits in tumors is determined by photoaffinity labelling with 8-N₃-[³²P]cAMP followed by immunoprecipitation with 20 RI_α antibodies as described by Tortora et al. (*Proc. Natl. Acad. Sci. (USA)* (1990) 87:705-708). The photoactivated incorporation of 8-N₃-[³²P]cAMP (60.0 Ci/m-mol), and the immunoprecipitation using the anti-RI_α or anti-RII_β antiserum and protein A 25 Sepharose and SDS-PAGE of solubilized antigen-antibody complex follows the method previously described (Tortora et al. (1990) *Proc. Natl. Acad. Sci. (USA)* 87:705-708; Ekanger et al. (1985) *J. Biol. Chem.* 260:3393-3401). It is expected that the amount of 30 RI_α in tumors treated with hybrid, inverted hybrid, and inverted chimeric oligonucleotides of the invention will be reduced compared with the amount in tumors treated with mismatch, straight phosphorothioate, or straight phosphodiester 35 oligonucleotide controls, saline, or other controls.

EXAMPLE 12**cAMP-Dependent Protein Kinase Assays**

5 Extracts (10 mg protein) of tumors from
antisense-, control antisense-, or saline-treated
animals are loaded onto DEAE cellulose columns (1
x 10 cm) and fractionated with a linear salt
gradient (Rohlf et al. (1993) *J. Biol. Chem.*
268:5774-5782). PKA activity is determined in the
10 absence or presence of 5 μ M cAMP as described
below (Rohlf et al. (1993) *J. Biol. Chem.* 268:5774-
5782). cAMP-binding activity is measured by the
method described previously and expressed as the
specific binding (Tagliaferri et al. (1988) *J. Biol.*
15 *Chem.* 263:409-416).

After two washes with Dulbecco's phosphate-
buffered saline, cell pellets (2×10^6 cells) are
lysed in 0.5 ml of 20 mM Tris (pH 7.5), 0.1 mM
20 sodium EDTA, 1 mM dithiothreitol, 0.1 mM
pepstatin, 0.1 mM antipain, 0.1 mM chymostatin,
0.2 mM leupeptin, 0.4 mg/ml aprotinin, and 0.5
mg/ml soybean trypsin inhibitor, using 100 strokes
of a Dounce homogenizer. After centrifugation
25 (Eppendorf 5412) for 5 min, the supernatants are
adjusted to 0.7 mg protein/ml and assayed (Uhler
et al. (1987) *J. Biol. Chem.* 262:15202-15207)
immediately. Assays (40 μ l total volume) are
performed for 10 min at 300°C and contained 200 μ M
30 ATP, 2.7×10^6 cpm γ [32 P]ATP, 20 mM MgCl_2 , 100 μ M
Kemptide (Sigma K-1127) (Kemp et al. (1977) *J. Biol.*
Chem. 252:4888-4894), 40 mM Tris (pH 7.5), \pm 100
 μ M protein kinase inhibitor (Sigma P-3294) (Cheng

et al. (1985) *Biochem. J.* 231:655-661), $\pm 8 \mu\text{M}$ cAMP
and 7 μg of cell extract. The phosphorylation of
Kemptide is determined by spotting 20 μl of
incubation mixture on phosphocellulose filters
5 (Whatman, P81) and washing in phosphoric acid as
described (Roskoski (1983) *Methods Enzymol.* 99:3-6).
Radioactivity is measured by liquid scintillation
using Econofluor-2 (NEN Research Products NEF-
969). It is expected that PKA and cAMP binding
10 activity will be reduced in extracts of tumors
treated with the hybrid, inverted hybrid, and
inverted chimeric oligonucleotides of the
invention.

15

EQUIVALENTS

Those skilled in the art will recognize, or
be able to ascertain, using no more than routine
5 experimentation, numerous equivalents to the
specific substances and procedures described
herein. Such equivalents are considered to be
within the scope of this invention, and are
covered by the following claims.

10

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: HYBRIDON, INC.
- (ii) TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND METHODS OF THEIR USE
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Hale and Dorr
 - (B) STREET: 60 State Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02109
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT (TO BE ASSIGNED)
 - (B) FILING DATE: HEREWITH
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/532,979
 - (B) FILING DATE: 22-SEPT-1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Kerner, Ann-Louise
 - (B) REGISTRATION NUMBER: 33,523
 - (C) REFERENCE/DOCKET NUMBER: HYZ-050PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-526-6000
 - (B) TELEFAX: 617-526-5000

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCGTGCCTCC TCACTGGC

18

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCGCGCCTCC TCGCTGGC

18

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCATGCTTCC ACACAGGC

18

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCGUGCCTCC TCACUGGC

18

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GCGCGCCTCC TCGCUGGC

18

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GCGTGCCUCC UCACTGGC

18

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCGCGCCUCC UCGCTGGC

18

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCATGCAUCC GCACAGGC

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCAUGCATCC GCACAGGC

18

What is claimed is:

1. A synthetic, modified oligonucleotide complementary to, and capable of down-regulating the expression of, nucleic acid encoding protein kinase A subunit RIa, the modified oligonucleotide having from about 15 to about 30 nucleotides and being a hybrid, inverted hybrid, or inverted chimeric oligonucleotide,
 - the hybrid oligonucleotide comprising a region of at least two deoxyribonucleotides, flanked by 3' and 5' flanking ribonucleotide regions each having at least four ribonucleotides, the inverted hybrid oligonucleotide comprising a region of at least four ribonucleotides flanked by 3' and 5' flanking deoxyribonucleotide regions of at least two deoxyribonucleotides, and the inverted chimeric oligonucleotide comprising an oligonucleotide nonionic region of at least four nucleotides flanked by two oligonucleotide phosphorothioate regions.
2. The oligonucleotide of claim 1 having 18 nucleotides.
3. The oligonucleotide of claim 1 which is a hybrid oligonucleotide.
4. The oligonucleotide of claim 3 having substantially the nucleotide sequence set forth in SEQ ID NO:4.

5. The oligonucleotide of claim 3 wherein each of the flanking ribonucleotide regions comprises at least four contiguous 2'-O-substituted ribonucleotides.
- 5 6. The oligonucleotide of claim 5 wherein each of the flanking ribonucleotide regions comprises at least one 2'-O-alkyl ribonucleotide.
- 10 7. The oligonucleotide of claim 6 wherein each of the flanking ribonucleotide regions comprises at least one 2'-O-methyl ribonucleotide.
- 15 8. The oligonucleotide of claim 5 wherein each of the flanking ribonucleotide regions comprises at least four 2'-O-methyl ribonucleotides.
- 20 9. The oligonucleotide of claim 3 wherein the ribonucleotides and deoxyribonucleotides are linked by phosphorothioate internucleotide linkages.
- 25 10. The oligonucleotide of claim 1 which is an inverted hybrid oligonucleotide.
11. The oligonucleotide of claim 10 having substantially the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:6.
- 30 12. The oligonucleotide of claim 10 wherein the ribonucleotide region comprises at least five contiguous ribonucleotides.

13. The oligonucleotide of claim 12 wherein the deoxyribonucleotide flanking regions comprise six contiguous ribonucleotides.
- 5 14. The oligonucleotide of claim 10 wherein the flanking ribonucleotide regions comprise 2'-O-substituted ribonucleotides.
- 10 15. The oligonucleotide of claim 16 wherein the 2'-O-substituted ribonucleotides is a 2'-O-alkyl substituted ribonucleotide.
- 15 16. The oligonucleotide of claim 15 wherein each of the flanking ribonucleotide regions comprise at least one 2'-O-methyl ribonucleotide.
- 20 17. The oligonucleotide of claim 10 wherein the nucleotides are linked by phosphorothioate internucleotide linkages.
- 25 18. A composition of matter for inhibiting the expression of protein kinase A with reduced side effects, the composition comprising the inverted hybrid oligonucleotide of claim 12.
- 30 19. The oligonucleotide of claim 1 which is an inverted chimeric oligonucleotide.
20. The oligonucleotide of claim 19 having substantially the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

21. The oligonucleotide of claim 19 wherein the oligonucleotide nonionic region comprises about 4 to about 12 nucleotides.
- 5 22. The oligonucleotide of claim 21 wherein the oligonucleotide nonionic region comprises six nucleotides.
- 10 23. The oligonucleotide of claim 19 wherein the oligonucleotide nonionic region comprises alkylphosphonate nucleotides.
- 15 24. The oligonucleotide of claim 23 wherein the oligonucleotide nonionic region comprises methylphosphonate nucleotides.
- 20 25. The oligonucleotide of claim 19 wherein the nucleotides in the flanking regions comprise at least six contiguous nucleotides linked by phosphorothioate internucleotide linkages.
- 25 26. A composition of matter for inhibiting the expression of the protein kinase A RI_α subunit gene with reduced side effects, the composition comprising the inverted chimeric oligonucleotide of claim 19.
- 30 27. A method of inhibiting the proliferation of cancer cells *in vitro* comprising the step of administering the oligonucleotide of claim 1 to the cells.

28. A method of inhibiting the proliferation of cancer cells *in vitro* comprising the step of administering the oligonucleotide of claim 3 to the cells.

5

29. A method of inhibiting the proliferation of cancer cells *in vitro* comprising the step of administering the oligonucleotide of claim 10 to the cells.

10

30. A method of inhibiting the proliferation of cancer cells *in vitro* comprising the step of administering the oligonucleotide of claim 19 to the cells.

15

31. A therapeutic composition comprising the oligonucleotide of claim 1 in a pharmaceutically acceptable carrier.

20

32. A therapeutic composition comprising the oligonucleotide of claim 3 in a pharmaceutically acceptable carrier.

25

33. A therapeutic composition comprising the oligonucleotide of claim 10 in a pharmaceutically acceptable carrier.

30

34. A therapeutic composition comprising the oligonucleotide of claim 19 in a pharmaceutically acceptable carrier.

35. A method of treating cancer in an afflicted subject comprising the step of administering to the subject the therapeutic composition of claim 31.

5

36. A method of treating cancer in an afflicted subject comprising the step of administering to the subject the therapeutic composition of claim 32.

10


37. A method of treating cancer in an afflicted subject with reduced side effects, the method comprising the step of administering to the subject the therapeutic composition of claim 33.

15

38. A method of treating cancer in an afflicted subject with reduced side effects, the method comprising the step of administering to the subject the therapeutic composition of claim 34.

20

1/1

**FIG. 1**

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/15084

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/11 A61K31/70 C07H21/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 490 077 A (FORYOU CORP) 17 June 1992 cited in the application see the whole document	1-38
Y	--- WO 94 23028 A (HYBRIDON INC ;AGRAWAL SUDHIR (US); TANG JIN YAN (US); PADMAPRIYA A) 13 October 1994 see page 6, line 2 - line 8 see page 12, table 1, CMPD C, CMPD J and CMPD K see page 18, line 3 - page 19, line 6 see example 4 see claims 17-28 --- -/--	1-9,27, 28,31, 32,35,36

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

20 February 1997

Date of mailing of the international search report

07.03.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/15084

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
O,Y	<p>PROC ANNU MEET AM ASSOC CANCER RES, (MARCH 1995). 36, PAGE 411. ABSTRACT 2450., XP002025691</p> <p>LU, Z. ET AL.: "In vivo stability, pharmacokinetics, and metabolism of a ' hybrid ' oligonucleotide phosphorothioate in rats."</p> <p>see abstract</p> <p>& EIGHTY-SIXTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, TORONTO, ONTARIO, CANADA, MARCH 18-22, 1995,</p> <p>---</p>	<p>1,2, 10-27, 29-31, 33-35, 37,38</p>
A	<p>BIOCHEMICAL PHARMACOLOGY, (1995 AUG 8) 50 (4) 545-56., XP000644798</p> <p>ZHANG, R. ET AL.: "In vivo stability, disposition and metabolism of a " hybrid " oligonucleotide phosphorothioate in rats."</p> <p>see the whole document, especially page 555, last paragraph</p> <p>---</p>	<p>1-38</p>
A	<p>ANTISENSE RESEARCH AND DEVELOPMENT, vol. 4, 1994, US, pages 201-206, XP002025692</p> <p>GALBRAITH, W. ET AL.: "Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey"</p> <p>cited in the application</p> <p>---</p>	
A	<p>NATURE MEDICINE, vol. 1, June 1995, pages 528-533, XP002025693</p> <p>NESTEROVA, M. & CHO-CHUNG, Y.: "A single injection protein kinase A-directed antisense treatment to inhibit tumour growth"</p> <p>cited in the application</p> <p>see the whole document</p> <p>---</p>	<p>1,26,31, 35</p>
A	<p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 19, 5 July 1993, pages 14514-14522, XP000576145</p> <p>MONIA, B. ET AL.: "EVALUATION OF 2'-MODIFIED OLIGONUCLEOTIDES CONTAINING 2'-DEOXY GAPS AS ANTISENSE INHIBITORS OF GENE EXPRESSION"</p> <p>see the whole document</p> <p>---</p>	<p>1,10, 12-17</p>

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 96/15084

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MOLECULAR BIOLOGY REPORT, vol. 18, no. 3, October 1993, pages 217-221, XP000610055 PISETSKY, D. & REICH, C.: "STIMULATION OF IN VITRO PROLIFERATION OF MURINE LYMPHOCYTES BY SYNTHETIC OLIGODEOXYNUCLEOTIDES" ---	
P,X	WO 96 16976 A (POLA CHEM IND INC) 6 June 1996 see abstract see SEQ ID 5 ---	1-3,10, 12,13, 18, 27-29, 31-33, 35-37
T	BIOCHEMICAL PHARMACOLOGY, vol. 51, no. 2, 26 January 1996, pages 173-182, XP000610208 ZHAO, Q. ET AL.: "EFFECT OF DIFFERENT CHEMICALLY MODIFIED OLIGODEOXYNUCLEOTIDES ON IMMUNE STIMULATION" see the whole document ---	1-38
T	WO 96 31600 A (HYBRIDON INC) 10 October 1996 see the whole document ---	1-38
T	BIOORGANIC AND MEDICINAL CHEMISTRY, (1996) 4/10 (1685-1692)., XP000644792 YU, D. ET AL.: "Hybrid oligonucleotides: Synthesis, biophysical properties, stability studies, and biological activity." see the whole document -----	1-3, 5-10, 12-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/15084

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0490077	17-06-92	US-A- 5271941 CA-A- 2054325 JP-A- 8310958 JP-A- 6211889 ZA-A- 9203666	21-12-93 03-05-92 26-11-96 02-08-94 22-11-93
WO-A-9423028	13-10-94	AU-A- 6527094 CA-A- 2159350 CN-A- 1124980 EP-A- 0693123 JP-T- 8510900	24-10-94 13-10-94 19-06-96 24-01-96 19-11-96
WO-A-9616976	06-06-96	NONE	
WO-A-9631600	10-10-96	AU-A- 5325696	23-10-96

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 15084

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 35-38
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 14-16
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

See continuation sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

3 subjects. See continuation sheet PCT/ISA/210

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 96/ 15084

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Subject 1) Claims 3-9,28,32,36 (complete) and 1-2,27,31,35 (partially):
Hybrid oligonucleotides for down-regulating PKA RI-alpha,
composition and methods for using them.

Subject 2) Claims 10-18,29,33,37 (complete) and 1-2,27,31,35 (partially):
id. for the inverted hybrid oligonucleotides.

Subject 3) Claims 19-26,30,34,38 (complete) and 1-2,27,31,35 (partially):
id. for the inverted chimeric oligonucleotides.

Continuation of Box I, point 2:

Claims 14 to 16 are drawn to oligonucleotides having flanking ribonucleotide regions, which is in complete contradiction with claim 10 they depend on. Indeed, claim 10 is drawn to an inverted hybrid oligo which (as defined in claim 1) has DEOXYribonucleotide flanking regions. Therefore, claims 14 to 16 have been read and searched as having a central ribonucleotidic region in conformity with claim 10.